Wanhuida Intellectual Property
Sponsored
Sponsored
-
Sponsored by Wanhuida Intellectual PropertyMinnan (Miranda) Xie of Wanhuida Intellectual Property provides a guide to drafting patent applications in the burgeoning area of personalised medicine and companion diagnostics, thereby avoiding the ineligibility pitfall and ensuring adequate protection -
Sponsored by Wanhuida Intellectual PropertyTwo invalidation decisions involving the US pharmaceutical company provide guidance on the building of a patent portfolio in China and the filing of supplementary experimental evidence, says Yue Guan of Wanhuida Intellectual Property
-
Sponsored by Wanhuida Intellectual PropertyWu Xiaohui of Wanhuida Intellectual Property reports on an invalidation decision that demonstrates the importance of patentees limiting and generalising technical features in claims so that they can be sufficiently supported by the specification
-
Sponsored by Wanhuida Intellectual PropertyWu Xiaoping of Wanhuida Intellectual Property analyses a decision that carries great weight in differentiating between monopolistic behaviour and the exercise of valid intellectual property rights
-
Sponsored by Wanhuida Intellectual PropertyHonghui Hu of Wanhuida Intellectual Property explains that a CNIPA ruling on a patent covering an antidepressant could help to determine the patentability of pharmaceutical compounds
-
Sponsored by Wanhuida Intellectual PropertyWu Xiaohui of Wanhuida Intellectual Property explains a pioneering case heard by the Intellectual Property Court of the Supreme People’s Court and considers its implications for original and generic drug makers
